BriaCell Therapeutics Corp. (BCTX) stock
Close on Nov 12, 2026Market cap $30.65MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jul 31, 2026
Valuation
- Market cap
- $30.65M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -93.89%
Fundamentals
- Net income
- -$34.90M
- EPS, diluted
- -$6.97
- Free cash flow
- -$28.78M
- Diluted shares
- 8M
Trading
- Previous close
- $3.59
- Open
- $3.59
- Day's range
- $3.39 – $3.65
- Volume
- 44,784
- Average volume (20 days)
- 68,226
- Beta (5 years)
- 0.89
- 52-week range
- $2.60 – $13.09
- RSI (14 days)
- 48.8
- Volatility (1 year)
- 113.6%
- Relative volume
- 0.20×
- WACC
- 9.3%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | BCTX | S&P 500 | Difference | BCTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.3% | -2.7% | −6.6 pts | ||
| 3 months | +2.9% | -1.7% | +4.7 pts | ||
| Year to date | -50.6% | +11.9% | −62.5 pts | ||
| 1 year | -65.3% | +12.0% | −77.3 pts | ||
| 3 years | -99.4% | +78.2% | −177.6 pts | -81.9% | +21.2% |
| 5 years | -99.8% | +73.2% | −173.0 pts | -70.3% | +11.6% |
Eight years at a glance
Fiscal years 2019 to 2026, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases BriaCell Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- News
- Update
- Update
About BriaCell Therapeutics
Pharmaceutical Preparations
BriaCell Therapeutics Corp. is a biotechnology company focused on developing targeted immunotherapies for cancer management. The company concentrates on the clinical research and scientific advancement of cell therapies designed to stimulate the immune system against tumor targets, notably advanced metastatic breast cancer. Its operational activities encompass internal research initiatives, patent development, and collaborations alongside specialized institutions such as the National Cancer Institute to advance therapeutic pipelines for individuals living with complex malignancies.
Company profile, executives and historyBriaCell Therapeutics stock: common questions
What is BriaCell Therapeutics's stock price?
BCTX closed at $3.51 on Nov 12, 2026, down 2.23% on the day. Over the past 52 weeks it traded between $2.60 and $13.09.
What is BriaCell Therapeutics's market cap?
BriaCell Therapeutics was worth $30.65M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is BCTX's P/E ratio?
BriaCell Therapeutics lost money over fiscal 2026 (diluted EPS -$6.97), so it has no meaningful P/E ratio.
Does BriaCell Therapeutics pay a dividend?
No. BriaCell Therapeutics has not paid a cash dividend over the last twelve months.
How has BCTX stock performed over the past year?
Including dividends, BCTX returned -65.3% over the past year, against +12.0% for the S&P 500.
Who are BriaCell Therapeutics's competitors?
Companies most similar to BriaCell Therapeutics by business, industry and size include ANIX, NWBO, ONCY, MAIA, MDNAF.
See a number that looks wrong?